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Abstract
Background: The Mre11/Rad50/Nbs1 (MRN) complex is a regulator of cell cycle checkpoints and DNA repair.
Defects in MRN can lead to defective S-phase arrest when cells are damaged. Such defects may elicit sensitivity to
selected drugs providing a chemical synthetic lethal interaction that could be used to target therapy to tumors
with these defects. The goal of this study was to identify these defects in the NCI60 panel of cell lines and identify
compounds that might elicit selective cytotoxicity.
Methods: We screened the NCI60 panel in search of cell lines that express low levels of MRN proteins, or that fail
to arrest in S-phase in response to the topisomerase I inhibitor SN38. The NCI COMPARE program was used to
discover compounds that preferentially target cells with these phenotypes.
Results: HCT116 cells were initially identified as defective in MRN and S phase arrest. Transfection with Mre11 also
elevated Rad50 and Nbs1, and rescued the defective S-phase arrest. Cells of the NCI60 panel exhibited a large
range of protein expression but a strong correlation existed between Mre11, Rad50 and Nbs1 consistent with
complex formation determining protein stability. Mre11 mRNA correlated best with protein level suggesting it was
the primary determinant of the overall level of the complex. Three other cell lines failed to arrest in response to
SN38, two of which also had low MRN. However, other cell lines with low MRN still arrested suggesting low MRN
does not predict an inability to arrest. Many compounds, including a family of benzothiazoles, correlated with the
failure to arrest in S phase. The activity of benzothiazoles has been attributed to metabolic activation and DNA
alkylation, but we note several cell lines in which sensitivity does not correlate with metabolism. We propose that
the checkpoint defect imposes an additional mechanism of sensitivity on cells.
Conclusions: We have identified cells with possible defects in the MRN complex and S phase arrest, and a series
of compounds that may preferentially target S phase-defective cells. We discuss limitations of the COMPARE
program when attempting to identify compounds that selectively inhibit only a few cell lines.
Background
Many anticancer agents kill cells as a consequence of
damaging their DNA. While this approach targets rapidly
proliferating cells, it is only somewhat selective for tumors
and can lead to undesirable toxicity to the patient. Differ-
ences exist between normal and tumor cells with respect
to the cellular response to DNA damage and it may be
possible to exploit these differences to selectively target
tumor cells. One such difference is in cell cycle checkpoint
regulation. In response to DNA damage, cell cycle check-
points are activated causing the arrest of cell cycle pro-
gression [1]. This allows the cell time to repair the
damage, or if too much damage has occurred, undergo
cell death. Defects in checkpoints lead to mutations and
cancer, and this genomic instability is now considered a
characteristic of tumors [2]. As the checkpoints function
to protect the cells from damage, it is hoped that their
selective defect in tumor cells may result in sensitivity to
novel therapeutic strategies.
The S-phase checkpoint is activated in response to
DNA damage that occurs during replication. For exam-
ple, topoisomerase I inhibitors such as SN38 produce a
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double-strand break upon collision with the replication
fork [3]. The MRN complex, consisting of Mre11,
Rad50 and Nbs1, is recruited to the double-strand break
and initiates the S-phase checkpoint by recruiting
ataxia-telangiectasia-mutated (ATM) to the damaged
site [4]. Processing at the break by the Mre11 nuclease
generates regions of single-stranded DNA that recruit
the ATM- and Rad3-related kinase (ATR) [5]. Activated
ATR and ATM phosphorylate the checkpoint kinases
Chk1 and Chk2, respectively, which in turn phosphory-
late CDC25A targeting it for degradation and effectively
arresting DNA synthesis through inactivation of the
Cdk2/Cyclin A complex [6,7].
Mutations in the MRN complex have been identified
in lymphoid, breast and colorectal tumors [8,9]. A defect
in the MRN complex has also been identified in the col-
orectal tumor cell line, HCT116 [9]. Such mutations
result in radioresistant DNA synthesis (RDS) and hyper-
sensitivity to ionizing radiation [10-12]. In addition,
MRN mutations have been reported to increase sensitiv-
ity towards anticancer drugs, such as topoisomerase I
inhibitors and cisplatin [13,14].
Studies in our laboratory have confirmed that
HCT116 cells have very low levels of Mre11 and also
that they arrest poorly in S phase in response to SN38.
By transfecting HCT116 cells with a vector expressing
Mre11, we show here that we can reconstitute the MRN
complex. Our data indicate that Mre11 is necessary for
the stability of Rad50 and Nbs1 and rescues the S-phase
arrest in HCT116.
MRN defects if present in some tumors could render
these cells sensitive to DNA-damaging agents and
thereby provide a tumor selective therapy. The primary
goal of these studies was to find compounds that prefer-
entially target cells with defects in the proteins of the
MRN complex. We have examined the frequency of
MRN defects across the NCI60 cell line panel which is
derived from many different cancer types (albeit only 59
are presently available) [15]. These cell lines have been
characterized pharmacologically by exposure to more
than 100,000 compounds (http://dtp.nci.nih.gov). We
then correlated the MRN protein levels to sensitivity to
the compounds in the NCI database using the COM-
PARE program [16,17]. Since there are many other pro-
teins involved in the S-phase checkpoint we also
assessed the cell lines for their ability to arrest in S
phase when incubated with SN38, and then searched
the database for additional correlations.
Methods
Cell culture
NCI60 cancer cell lines were obtained from the Devel-
opmental Therapeutics Program at the National Cancer
Institute and were cultured in RPMI 1640 media
(Hyclone) supplemented with 10% heat-inactivated fetal
bovine serum (Hyclone) and Antibiotic-antimycotic
(Gibco). Cells were cultured at 37°C with 5% CO2.
Elevated expression of Mre11 was achieved by cloning
Mre11 from pDB20 (obtained from John Petrini, Mem-
orial Sloan-Kettering Cancer Center) into pCR3.1 (Invi-
trogen) [18]. This plasmid was transfected into HCT116
cells using lipofectamine (Invitrogen), according to the
manufacturer’s protocol. Cells were selected in G418
(500 μg/ml) and multiple colonies were screened for
maximum expression.
Drugs and chemicals
SN38, the active metabolite of irinotecan, was obtained
from Pfizer, and 2-(4-amino-3-methylphenyl)-5-fluoro-
benzothiazole (5F 203, NSC 703786) was obtained from
the Developmental Therapeutics Program at the
National Cancer Institute (Bethesda, MD). Both drugs
were dissolved in DMSO and stored at -20°C.
Flow cytometry
For cell cycle analysis, cells were rinsed with phosphate-
buffered saline (PBS), harvested with 0.05% trypsin, and
fixed in 70% ethanol overnight. Cells were stained with
100 μg/ml propidium iodide in 1 mg/ml ribonuclease A
and analyzed on a FACScan flow cytometer (Becton
Dickinson).
Immunoblotting
Following treatment, cells were rinsed with phosphate
buffered saline, lysed by direct addition of Laemmli buf-
fer to the wells, boiled for 5 min, and stored at -80°C.
Protein levels were quantified using EZQ Protein Quan-
titation Kit (Molecular Probes). 15 μgo fe a c hl y s a t ew a s
separated by SDS-PAGE, and transferred to polyvinyli-
dene difluoride membranes. Membranes were blocked
and incubated overnight at 4°C with primary antibodies
specific for Nbs1 (Cell Signaling), Rad50 (Novus Biologi-
cals), Mre11 or actin (Calbiochem). Membranes were
washed and incubated for 30 min at room temperature
with anti-rabbit or anti-mouse secondary antibody con-
jugated to horseradish peroxidase. Proteins were visua-
lized with enhanced chemiluminescence. Densitometry
scans were quantified using Scion Image software (Scion
Corporation) and normalized to a serial dilution of the
same protein from MDA-MB-231 present on each blot.
Several exposures of each western blot were scanned to
avoid over-exposure and to ensure that the samples
were within the range of the standards.
Cell growth assays
Cells were seeded at low density (500-1000 cells) in 96-
well plates and then incubated with drug for 24 h.
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fresh media for 5-7 days at 37°C. Prior to attaining con-
fluence, cells were washed, lysed, and stained with
Hoechst 33258, as previously described [19]. Fluores-
cence was read on a microplate spectrofluorometer
(Spectramax M2). Within each experiment, each treat-
ment was repeated in at least eight wells. Sensitivity to
the “NSC” compounds was determined by the Develop-
mental Therapeutics program at NCI and the data were
obtained from their web site (http://dtp.nci.nih.gov). In
their screen, all cell lines were incubated with a range of
drug concentrations, usually for 48 h, and then fixed
and stained with sulforhodamine B.
Results
Mre11 rescues S-phase arrest in HCT116 cells
DNA damage, such as that caused by the topoisomerase
I inhibitor SN38, triggers checkpoints that arrest cell
cycle progression to allow for DNA repair. We have pre-
viously compared seven cell lines for their ability to
arrest in S phase [20]. In general, most cell lines arrest
in late, middle or early S phase as the SN38 concentra-
tion increases. However, we found that HCT116 cells
were notably different in that they showed primarily G2
arrest at high concentrations of SN38. Other studies
have demonstrated that HCT116 cells have low levels of
the MRN complex [9]. We confirmed that these cells
have very low expression of Mre11 protein compared to
MDA-MB-231 cells, as measured by western blotting
(Figure 1). Rad50 and Nbs1 levels were also low in
HCT116. Since Mre11 has been shown to be involved
in the S-phase checkpoint, we hypothesized that the
Mre11 defect was responsible for the lack of S-phase
arrest in HCT116 cells. To test this hypothesis, we
transfected HCT116 cells with a vector expressing
Mre11. We selected individual colonies that expressed
higher levels of Mre11 protein over control or vector-
transfected cells (Figure 1). HCT116+Mre11 cells not
only had increased levels of Mre11, but also had higher
levels of Rad50 and Nbs1 proteins, suggesting that the
protein stability of Rad50 and Nbs1 depends upon com-
plex formation with Mre11. Similar results were also
obtained in an earlier study that transfected Mre11 into
HCT116 cells [21]. Importantly, we also show that
expression of Mre11 rescued SN38-induced S-phase
arrest in HCT116 cells (Figure 1). We conclude that the
failure of HCT116 cells to arrest in S phase on SN38 is
due to their very low level of MRN.
MRN complex protein levels vary greatly across the cell
lines of the NCI60 panel
The National Cancer Institute has screened more than
100,000 compounds in a panel of 60 cell lines and this data
is publicly available. The database also has information on
the gene expression patterns in each cell line. However,
our data in Figure 1 suggests that MRN proteins are
primarily regulated by stability so their levels are unli-
kely to be reflected by mRNA levels. In order to deter-
mine the frequency of defects in the MRN complex we
made lysates from all of the cell lines. We assessed
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Figure 1 Expression of Mre11 rescues S-phase arrest in
HCT116. HCT116 cells were transfected with a vector expressing
Mre11 or an empty control vector and stable clones were selected.
(A) Cells were lysed and Mre11, Rad50, Nbs1, and actin proteins
were analyzed by western blot. The nine lanes on the right are
derived from 9 independently-transfected clones. (B) HCT116 cells
and two HCT116+Mre11 clones were incubated with 0-30 ng/ml
SN38 for 24 h. Cells were fixed, stained with propidium iodide and
analyzed for cell cycle distribution by flow cytometry.
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Page 3 of 13expression of Mre11, Rad50 and Nbs1 by western blot,
and quantified the intensity of the protein bands (Fig-
ure 2A, B and Table S1 in Additional File 1). Expres-
sion of each protein was assessed relative to the levels
in MDA-MB-231 which was set at a value of 1. There
was a large range of expression with relative protein
levels ranging from 0.06 to 2.4 for Mre11. There was
also more than 10-fold difference in protein levels of
Rad50 and Nbs1 (0.23 to 3.1 for Rad50, and 0.19 to
2.4 for Nbs1). There was a strong correlation between
protein levels when we compared Mre11/Rad50,
Mre11/Nbs1 and Rad50/Nbs1 (Figure 3A-C). This is
consistent with our finding that transfection with
Mre11 also increased Rad50 and Nbs1 levels. In addi-
tion to HCT116, a number of other cell lines expressed
low levels of Mre11, in particular U251 had levels as
low as HCT116. The next 5 lowest cell lines were
HL60, MALME-3M, SK-MEL-2, IGROV1 and TK10.
Each of these cell lines also had relatively low levels of
Rad50 and Nbs1, consistent with the intact complex
regulating the stability of each protein.
While this analysis was designed to identify cell lines
with low levels of the MRN proteins, we also identified
several lines in which the ratio of these proteins far
exceeded the expected values. For example, SW620 cells
had about 10 fold more Mre11 than Rad50, whereas
Nbs1 was intermediate between these two levels. On the
other hand, HCC2998, K562 and EKVX had about 2
fold more Rad50 than Mre11. For these latter cell lines,
Mre11 and Nbs1 were relatively similar suggesting that
it is the elevated level of Rad50 that maybe abnormal.
Whether these cell lines contain functionally defective
MRN remains to be determined.
To extend this analysis further, we compared the pro-
tein levels to mRNA levels obtained from the NCI data-
base (Figure 2C and Table S1 in Additional File 1). The
correlation coefficient for Mre11 mRNA and protein
was 0.55, but only 0.24 and 0.15 for Rad50 and Nbs1,
respectively (Figure 3D-F). This observation suggests
that Mre11 protein levels arem o r eh i g h l yr e g u l a t e db y
mRNA levels whereas the Rad50 and Nbs1 protein
levels are relatively independent of mRNA levels and
likely depend more on protein stability mediated via for-
mation of the MRN complex. It is also important to
note that most of the cells we identified as having low
levels of Mre11 protein had relatively normal levels of
MRN mRNA suggesting that, like HCT116, they may
contain a defective protein rather than the level of pro-
tein being regulated at the transcriptional level. The one
notable exception was IGROV1 which has a very low
level of Mre11 mRNA; surprisingly, these cells also
exhibited a very low level of mRNA for Rad50. There-
fore in this case, it appears that the reduced levels of
the MRN complex are a consequence of transcription.
Correlations between MRN protein levels and NCI60
compound activity
Considering that defective MRN can cause chemo- and
radio-sensitivity, we hypothesized that other drugs in
the NCI database would correlate with the low levels of
MRN observed. Accordingly, we used the NCI COM-
PARE program to find correlations between MRN pro-
teins and compound activity. We set the correlation
coefficient to 0.5 to restrict the number of compounds
identified. The search recovers both positive and nega-
tive correlations, that is, a positive correlation represents
high protein level correlating with sensitivity whereas a
negative correlation represents a cell line with low pro-
tein but high sensitivity to a compound. Mre11 and
Nbs1 protein levels correlated with the activity of only a
few compounds, and approximately equally distributed
between positive and negative correlations (Table 1). In
contrast, Rad50 protein levels correlated with many
compounds, most of them positive. Three compounds
were identified twice in the search, once each for Mre11
and Rad50 proteins. NSC 734406 correlated with low
levels of Mre11 and Rad50 and therefore warrants vali-
dation and further study (Figure 4). The other two com-
pounds, NSC359452 and NSC740487, correlated with
high Mre11 and Rad50, but further examination of the
dose response curves revealed the compounds were only
marginally active in HCC2998 and HT29 cells and not
in the other cell lines even at the highest concentration
tested (10
-4 M). Hence, sensitivity to these latter com-
pounds does not correlate with expression of the MRN
proteins. This reflects a limitation of the COMPARE
program that is discussed below.
Lack of S-phase arrest in cell lines correlates with the
activity of compounds, including several benzothiazoles
While the MRN complex has a critical role in the S-
phase checkpoint, there are many other proteins that
are also involved. In search of other possible S phase
checkpoint defects, we screened all of the cell lines in
the NCI60 panel for their ability to S-phase arrest in
response to the topoisomerase I inhibitor SN38 (Figure
5). Several of the cell lines exhibited multiple peaks in
untreated cells which is due to a mix of diploid and tet-
raploid cells. A mid S-phase arrest is observed in most
of the cell lines when incubated with 3 - 10 ng/ml
SN38. Several cell lines exhibited much more marked S-
phase arrest at lower concentrations of SN38, for exam-
ple T47D. One cell line, HL60, showed predominantly
sub-G1 DNA content above 3 ng/ml indicative of apop-
tosis rather than arrest. Of the 59 cells lines tested,
there were four that primarily arrested in G2 phase
rather than S at the maximum concentration tested:
HCT116, IGROV1, TK-10 and HCC2998 (these cell
lines are designated “100” in Figure 6). Interestingly, the
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Figure 2 MRN protein and mRNA levels in the NCI60 panel. (A) Cell lines of the NCI60 panel were lysed and Mre11, Rad50, and Nbs1
proteins were analyzed by western blot. Lysates from each cell line were loaded in duplicate and three concentrations of MDA-MB-231 were
loaded in duplicate on each gel. A representative blot is shown. (B) Multiple exposures of the western blots were scanned and quantified using
Scion Image software. Protein levels were normalized to MDA-MB-231 = 1. (C) mRNA levels for Mre11, Rad50 and Nbs1 were derived from an
Affymetrix human genome U133A-B array and obtained from the NCI Developmental Therapeutics Program database (http://dtp.nci.nih.gov;
experiment ID# 223469). Values were normalized to MDA-MB-231 = 1. The numerical values for the data in panels B and C are provided as Table
S1 in Additional file 1.
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Page 5 of 13first three of these cell lines also had low MRN levels.
For these cell lines, it is possible that the low MRN can
explain their S-phase defect. In contrast, HCC2998 had
one of the highest levels of Mre11 but lacked S-phase
arrest. One possibility as discussed above is that the
high Mre11 might reflect a functional defect in Mre11
and this would then explain their S-phase defect.
However, several other cell lines, including U251 and
HL-60, had low levels of MRN, but were still proficient
for S-phase arrest, hence the level of MRN does not by
itself predict whether a cell will arrest.
Using the COMPARE program to analyze the values
in Figure 6, we identified 157 compounds that corre-
lated with the lack of S arrest, but only 11 compounds
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Page 6 of 13that had a negative correlation (top 10 hits shown in
Table 2). The correlation coefficients for the top com-
pounds were much higher than those observed for cor-
relations with MRN expression shown in Table 1. The
top 30 compounds were analyzed individually. It was
noted that many compounds exhibited poor correlation
with the cell lines that failed to S-phase arrest, rather
the relatively high correlation coefficients resulted from
strong correlation with the other 55 cell lines rather
than the 4 that failed to arrest. However, six of the top
30 correlations all derived from a single cluster (k15.21)
of the 3dMind Map, a self organizing map which clus-
ters similar cytotoxicity data into a two dimensional
visual translation of related compounds (Figure 7).
These clusters generally reflect compounds with a simi-
lar mechanism of action, although cluster k15.21 is
unrelated to any common anticancer mechanism. About
half of the compounds in this cluster, have closely
related structures and are known as benzothiazoles,
although other structures such as NSC 680467 also
showed high correlation with cells that failed to S phase
arrest. The correlation with S phase arrest for two of
the benzothiazoles is shown in Figure 8. In general,
most of the compounds in cluster k15.21 inhibit growth
of 5 cell lines, HCC2998, IGROV-1, TK10, MCF7 and
T47D (although the latter is not evident for the com-
pounds shown in Figure 6B), but only the first three of
these failed to arrest in S phase when incubated with
S N 3 8 .T ov a l i d a t et h e s er e sults, we obtained the ben-
zothiazole NSC 703786 (5F 203; the only one available
from NCI) and assessed growth inhibition in various cell
lines including those that lack S-phase arrest (Figure 9).
Our results were consistent with those from the NCI
database.
The sensitivity of cells to benzothiazoles is reported to
be due to the ability of cells to metabolically activate
these compounds which then go on to damage DNA
[22,23]. MCF7 cells exhibit the highest metabolism of
benzothiazoles and we therefore anticipated that they
should sensitize non-responsive cells in co-culture. We
used transwell plates in a 96 well format and plated
~50,000 MCF7 cells in the upper well. Other cell lines,
including HCT116, were plated at low density in the
lower wells. NSC703783 (1 μM) was added for 24 h
then removed, in an experiment similar to that in Figure
9. The MCF7 cells had no impact on the growth of six
cell lines tested. We conclude that differences in meta-
bolism do not adequately explain the differences in sen-
sitivity of cells to the benzothiazoles.
Discussion
The overall goal of this study was to identify molecular
defects in cell cycle checkpoint regulation using the
NCI60 panel of cell lines, and then to identify com-
pounds that might target cells with these defects. Even-
tually, such compounds might provide leads for the
development of drugs for personalized cancer therapy.
We began by screening the cell panel for potential
defects in MRN proteins and the S-phase checkpoint.
We uncovered a number of interesting relationships
with respect to MRN proteins and their mRNA that
impact the level of this complex. In addition, using the
COMPARE program, we have identified several com-
pounds of interest which warrant further study.
Our results implicate protein stability in the regulation
of MRN protein levels. Transfection with Mre11 not
only increased Mre11 levels but also Rad50 and Nbs1
levels. In comparing the protein levels in each cell line
Table 1 The highest correlating compounds for Mre11, Rad50 and Nbs1
Mre11 Rad50 Nbs1
Correlation Compound Correlation Compound Correlation Compound
0.542 NSC 654825 0.67 NSC 13728 0.527 NSC 640653
0.521 NSC 740847 0.622 NSC 686033 0.514 NSC 735029
0.517 NSC 647960 0.614 NSC 650947 0.509 NSC 704099
0.502 NSC 359452 0.605 NSC 371688 0.509 NSC 731647
0.601 NSC 2353286 0.508 NSC 674948
-0.543 NSC 734406 -0.54 NSC 656576 -0.567 NSC 622089
-0.534 NSC 736184 -0.506 NSC 106320 -0.558 NSC 636870
-0.514 NSC 713292 -0.501 NSC 734406 -0.522 NSC 627268
-0.512 NSC 681130 -0.515 NSC 683903
Positive correlations >0.5 = 4 Positive correlations >0.5 = 44 Positive correlations >0.5 = 8
Negative correlations >0.5 = 4 Negative correlations >0.5 = 3 Negative correlations >0.5 = 8
Bold = NSC 734406 that was identified two times.
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tion between the levels of these three proteins. The
overall level of the complex appeared to be primarily
regulated by transcription of Mre11 as there was much
lower correlation between mRNA and protein levels for
Rad50 and Nbs1. These results suggest that the protein
levels of Rad50 and Nbs1 are primarily regulated by sta-
bility of the complex while transcription of Mre11 con-
tributes more to the overall level of the complex.
W h i l eM r e 1 1e x p r e s s i o nm a yb em o r eh i g h l yr e g u -
lated by transcription, among the cell lines with low
levels of Mre11 protein, only the IGROV1 cells had a
very low level of mRNA. HCT116 had a relatively high
level of Mre11 transcript but low protein, and this has
been shown to be due to a splicing defect in its mRNA
[9]. This defect occurs as a frame shift in a poly(dA)
track in an intron which is consistent with these cells
being defective for mismatch repair MLH1 [9,24]. Five
cell lines in the NCI60 panel are defective for MLH1
[25], one of which is IGROV1, but the other three
(SKOV3, KM12 and CCRF-CEM) still express relatively
normal levels of Mre11. None of the NCI cell lines are
defective in the mismatch gene MSH2. Hence mismatch
repair defects do not appear to explain the low levels of
Mre11 protein in these other cell lines. Other mutations
which might result in protein degradation could be a
possible cause for the low protein levels in the other
cells but further study is necessary. In addition, there
were several cell lines with unbalanced levels of MRN,
for example, unexpected high or low levels of Rad50
compared to Mre11. One possible explanation for this
observation is that the proteins contain a mutation
which confers greater protein stability when they are
not in the MRN complex.
This screen identified a small number of compounds
which correlated with either Mre11, Rad50, or Nbs1.
However, there were three compounds identified which
correlated with both Mre11 and Rad50. The activity of
one of these, NSC 734406, was significant at the con-
centrations tested and correlates with low levels of
M r e 1 1a n dR a d 5 0( F i g u r e4 ) .V a l i d a t i o na n df u r t h e r
study with this compound is necessary to assess whether
it does preferentially kill cells with low MRN protein but
this was not possible as the compound is not available
from the NCI repository. One of the potential limita-
tions of this COMPARE analysis is that protein levels
may not necessarily reflect MRN function, particularly
in those cases where MRN protein expression is unba-
lanced. Another approach would be to assay the cells
for MRN activity using a functional readout, such as
Chk1 phosphorylation in response to ionizing radiation,
for which the MRN complex is required [26]. Alter-
nately the recruitment of ATM to damaged DNA could
be assayed as this also depends on the MRN complex.
Mre11 Rad50
high protein
sensitive
low protein
resistant
NSC 734406: 2,6-bis(benzylamino)-4-
(3-hydroxyphenyl)pyridine-3,5-dicarbonitrile
Figure 4 Correlation of Mre11 and Rad50 protein levels with
sensitivity to NSC 734406. Relative protein levels (open bars) are
compared to NSC 734406 sensitivity (red lines) in each cell line. The
sensitivity data was obtained from http://dtp.nci.nih.gov. The center
line in each data set reflects the mean for that parameter across the
entire panel, and then the results for each cell line are represented
to the left (low protein level or drug resistance) or to the right (high
protein or drug sensitivity) of the mean. The observation that the
red lines and boxes have an inverse correlation reflect the fact that
low protein level correlates with drug sensitivity.
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Page 8 of 13In searching the NCI60 panel for cell lines with
defects in the S-phase checkpoint we identified three
cell lines, in addition to HCT116, which failed to arrest
in S-phase in response to SN38. HCT116, TK-10 and
IGROV1 all have low levels of the MRN which may
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Figure 5 Comparison of the ability of NCI60 cell lines to arrest in S-phase when incubated with SN38. Cells were incubated with 0-30
ng/ml SN38 for 24 h then analyzed for cell cycle distribution by flow cytometry. The highlighted cell lines demonstrate little if any S arrest at
the highest concentration.
Concentration of SN38 that arrests cells in mid S phase (ng/ml)
("100" = failure to arrest)
not applicable
Figure 6 Summary of the ability of NCI60 cell lines to arrest in
S-phase when incubated with SN38. Representation of the
concentration of SN38 that arrested each cell line in mid-S phase as
determined in Figure 5. The cell lines in which no arrest was
observed are designated 100. HL60 cells underwent apoptosis rather
than arrest so no number is assigned.
Table 2 Compounds with the highest correlation with
SN38-induced S phase arrest
SN38-induced S phase arrest
Correlation Compound
0.82 NSC 691535
0.791 NSC 649554
0.752 NSC 680467
0.726 NSC 358873
0.721 NSC 648601
-0.7 NSC 641318
-0.65 NSC 677599
-0.644 NSC 615291
-0.592 NSC 633267
-0.541 NSC 638404
Positive correlations >0.5 = 157
Negative correlations >0.5 = 11
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Page 9 of 13explain their S phase defect (see summary in Figure 10).
In contrast, HCC2998 cells fail to arrest in S phase yet
have very high levels of Rad50 and Mre11 proteins. It
remains to be determined whether the MRN complex in
this cell line is functional. If functional, this would sug-
gest that while the MRN complex is necessary for S-
phase arrest, it is not sufficient. There were also several
cell lines with low levels of the MRN proteins that were
proficient for S-phase arrest. A possible explanation is
that low levels of MRN maybe sufficient for S-phase
arrest but that a mutation in Mre11 as occurs in
HCT116 may be necessary to elicit the checkpoint the
defect. For example, it has been suggested that the
mutant form of Mre11 in HCT116 acts in a dominant
negative manner and this may be far more detrimental
than simply having low levels of Mre11 [24].
We have previously reported an alternate means to
prevent S phase arrest [27]. The expression of shRNA
against Chk1 in MDA-MB-231 cells overcame the S
phase arrest induced by SN38, although such cells still
arrested in G2. We observed a similar response when
cells were co-incubated with SN38 and a small molecule
inhibitor of Chk1. There is a close link between the
MRN complex and Chk1 activation. Specifically, MRN
is recruited to double-strand breaks where the exonu-
clease activity of Mre11 creates single-stranded DNA
that, through a series of events, recruits ATR and acti-
vates Chk1. However, it has been shown that HCT116
cells are fully competent to activate Chk1 when
damaged with topoisomerase I inhibitors [21] and we
have confirmed this in our own laboratory (data not
shown). This is likely explained by the topoisomerase I
inhibitors stalling replication fork progression thereby
activating ATR and Chk1 without the need to implicate
ATM and Mre11. This raises the conundrum as to why
SN38 is fully capable of activating Chk1 in HCT116
NSC 691535
NSC 702154
NSC 703786
NSC 680467
NSC 358873
NSC 696154
Figure 7 Benzothiazoles highly correlate with lack of SN38-mediated S-phase arrest. The k15.21 cluster from the 3dMind Map from the
NCI60 database (http://spheroid.ncifcrf.gov/spheroid/). The compounds shown in red are in the top 30 correlations with lack of S- phase arrest.
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Page 10 of 13NSC 696154 NSC 702154
no S phase arrest
sensitive
S phase arrest
resistant
no S phase arrest
sensitive
S phase arrest
resistant
Figure 8 Correlation of sensitivity to representative benzothiazoles and lack of SN38-mediated S-phase arrest. The mean graphs for
sensitivity to NSC 696154 (left panel, red lines) or NSC 702154 (right panel, red lines) are compared to the concentration of SN38 which causes
S-phase arrest in each cell line (open bars). The observation that the red lines and boxes have a direct correlation reflect the fact that drug
sensitivity correlates with a deficiency in S phase arrest.
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Page 11 of 13cells yet the cells fail to S phase arrest unless they are
complemented with Mre11. The results suggest that
activation of Chk1 may be necessary but not sufficient
to induce S phase arrest and that the MRN complex
plays some additional role.
In searching for correlations between S-phase check-
point defects and compound activity, we identified many
drugs which correlated positively, meaning these com-
pounds have activity in cell lines with defects. Six com-
pounds out of the top 30 correlations identified mapped
to the same cluster indicating that they share the same
mechanism of growth inhibition. Four of these are ben-
zothiazoles, a class of compounds that has been shown
to be metabolized by sensitive cells and then form DNA
adducts [22,23]. Whether this is also true of other com-
pounds in this cluster has not been determined.
However, we note that KM12 cells have previously been
shown to metabolize benzothiazoles, yet they are insen-
sitive to these compounds [28]. Similarly we note that
TK10 cells are as sensitive as MCF7, yet have markedly
lower level of metabolism [22]. The lack of sensitivity of
HCT116 to benzothiazoles may be due to their inability
to metabolize the compound, however HCT116 cells
(and many others) remained insensitive to benzothia-
zoles when co-cultured with MCF7 cells. Accordingly,
while metabolism may contribute to the sensitivity to
these compounds in some cells, there may also be a
major contribution from the S-phase checkpoint defect.
The fact that the S-phase checkpoint search was a
functional assay provides greater confidence in the can-
didates identified than with the MRN protein screen.
However, because the S-phase defect can be caused by
multiple reasons (e.g., low or defective ATM, ATR,
Mre11 or Chk1), we may have missed many potential
drug candidates. Some compounds may correlate with
only some of the checkpoint defects responsible for the
lack of SN38-induced S-phase arrest. The fact that each
defect may be rare in the NCI60 panel makes it a chal-
lenge to use this approach to identify novel drug candi-
dates. For example, a compound that has the same
activity in 60 cell lines would exhibit a very high corre-
lation with a dataset in which 56 cell lines arrested and
4 did not, the correlation coefficient being driven by the
56 cell lines rather than the 4 interesting queries.
Accordingly, each compound discovered in the screen
had to be individually analyzed and validated. Many
compounds elicited no obvious correlation with the
query set. In some cases (e.g., NSC358873), three of the
four cell lines that failed to arrest in S phase had not
even been screened against this compound. These lim-
i t a t i o n sa r eu n f o r t u n a t eb e c a u s ew eh a dh o p e dt ou s e
this approach to identify compounds that killed only a
few cell lines, and might therefore be candidates for
selective therapy for tumors with that particular pheno-
type (i.e., individualized therapy). Given the limitations
of this screen, the fact that most of the cells defective
for S phase arrest were indeed sensitive to compounds
in the benzothiazole cluster gives strong support for
further investigation into this class of drugs.
Conclusions
G e n o m i ci n s t a b i l i t yi so n eo fthe characteristics of can-
cer and is frequently attributable to defects in DNA
damage response genes involved in either DNA repair
or checkpoint regulation. This provides a therapeutic
opportunity as these defective cells may be hypersensi-
tive to various drugs. We have identified cells with
potential defects in the MRN complex and in S phase
arrest, and a series of compounds that may preferentially
target S phase arrest-defective cells. The in silico screen
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Figure 9 Sensitivity of cells to the benzothiazole NSC 703786
(5F 203). Cells were incubated with 0 to 1 μM of NSC 703786 for
24 h. Drugs were removed and cells were grown for an additional
5-7 days. Cell growth was quantified by DNA content, as measured
by Hoechst 33258 staining.
Mre11 high
Mre11 low
S-phase arrest No S-phase arrest
HCT116+Mre11
MDA-MB-231
most cell lines
MDA-MB-231Δ Δ Δ ΔChk1
HCC2998
U251
SK-MEL-2
MALME-3M
HCT116
IGROV1
TK-10
Figure 10 The relationship between MRN protein expression
and ability of cells to arrest in S phase when incubated with
SN38.
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Page 12 of 13used has limitations when seeking compounds that are
cytotoxic to only a few cell lines. But considering this
limitation, the identification of benzothiazoles as com-
pounds that preferentially target cells with a defect in S
phase arrest warrants further investigation. Compounds
such as these that kill only a few cell lines likely repre-
sent the future of individualized cancer therapeutics.
Additional material
Additional file 1: Table S1: Correlations between Mre11, Rad50 and
Nbs1 protein and mRNA.
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